1. In Vivo

The E In ESG: Sustainability Goals Do Not Exempt Companies From Antitrust Compliance

 
• By Ashley Yeo

Regulatory interventions are the preferred route for ensuring sustainability compliance, says the OECD. Legal firm CMS notes that some ESG objectives may be in contravention of antitrust law. The EU is preparing guidelines on horizontal competition with a renewed focus on sustainability.

EU Green Deal
• Source: Shutterstock

More and more initiatives are being advanced to promote environmental compliance and sustainability. As In Vivo’s “E in ESG” series has described, health care companies and the life sciences industries are not exempt from the societal drive to slow the acceleration of climate change.

The duty of patient care means that providers and the medtech industry have a unique role in how they ensure...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ESG

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.